Option 5
Certain statements in this presentation contain or may contain "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are fo rward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could,"' "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue", the nega tive of these terms or other similar expressions, or the use of future dates, although not all forward-looking statements contain these words. Forward-looking statements may include, but are not limited to, statements regarding: our estimates of the annual total addressable global ma rket for our product and service offerings; our expectations about market trends, new product timing and success, including with respect to the an ticipated launch and success of the home product, and our anticipated future operating results. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applica ble risks and uncertainties include, but are not limited to the following: Vapotherm has incurred losses in the past and may be unable to a chieve or sustain profitability in the future or achieve its 2023 financial guidance including revenue growth, gross margin, cash operating exp ense reduction, and
reduced cash burn; risks associated with its manufacturing operations in Mexico; Vapotherm's ability to raise additional capital to fund its existing commercial operations, develop and commercialize new products, and expand its operations; Vapotherm's ability to com ply with its financial covenants, execute on its path-to-profitability initiative, convert excess inventory into cash and fund its business through 2023; Vapotherm's dependence on sales generated from its High Velocity Therapy systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability of Vapotherm's present and anticipated products to gain broad market acceptance; Vapotherm's inexperience directly marketing and selling its products; the potential loss
of one or more suppliers and dependence on its new third party manufacturer; Vapotherm's susceptibility to seasonal fluctuati ons; Vapotherm's failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or o ther intellectual property protection for its products; the impact of COVID on its business, including its supply chain, a possible delisting o f Vapotherm's
common stock and the other risks and uncertainties included under the heading "Risk Factors" in Vapotherm's Annual Report on Form 10-K for
the fiscal year ended December 31, 2022, as filed with the SEC on February 23, 2023, and its subsequent filings with the SEC, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to u pdate any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
The inventor of the heated humidified high flow category
Instrumental in making high flow a standard respiratory support in the acute care hospital setting
1999 | 2003 |
Vapotherm Incorporated | A Category is Born |
Vapotherm's technology was | Vapotherm releases first |
adopted from racehorses for | commercial heated high velocity |
clinical use | therapy product to market |
2016 | 2011 |
Non-inferior to NIPPV | High Flow MOA |
Study published in JAMAPediatrics shows | High flow therapy |
high velocity therapy to be non-inferior to | mechanisms of actions |
NiPPV for primary respiratory support for | defined |
neonates with RDS |
2018 | 2020 | |
Mask-Free NIV | New FDA Category | Firstline Defense for COVID |
Study published in Annals of Emergency | FDA clears high velocity therapy | Study published in CHEST shows the |
Medicine shows high velocity therapy to be | for expanded indications of use to | dispersion of aerosolized particles from high |
non-inferior to NiPPV for adult patients in | treat respiratory distress and/or | velocity therapy can be mitigated with a |
undifferentiated respiratory failure | hypoxemia. | simple surgical mask on the patient. |
Vapotherm is present in over 30% of the acute
care hospitals in the United States…
Vapotherm
2,000 acute care hospitals in 50 States
Internal data on file
…and in over 50 countries around the world
Over 3.3 million patients have been treated with Vapotherm high velocity therapy over the last 10 years
700000 | COVID-19 | ||||||||||
600000 | |||||||||||
500000 | |||||||||||
Number of Patients | |||||||||||
Treated with | |||||||||||
Vapotherm High | 400000 | ||||||||||
Velocity Therapy | |||||||||||
300000 | |||||||||||
200000 | |||||||||||
100000 | |||||||||||
0 | |||||||||||
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Internal data on file
During COVID, we met and kept our commitment to fulfill every customer order without raising pricing
- Ran 3 manufacturing shifts, 7 days a week
- Temporarily relocated 50+ assemblers to Exeter from out of state to support demand
- Paid premiums and expedite fees to suppliers
- Set-upunits on loading docks of hospital to immediately be placed on patients
Internal data on file
Post-COVID, we re-organized our operations to better serve our customers
North America
Vapotherm HQs
Manufacturing
Warehouse
R&D
Singapore
Euro Distribution Center
Netherlands
Vapotherm HQ
Exeter, NH
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Vapotherm Inc. published this content on 19 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 December 2023 12:17:34 UTC.